
    
      Sample selection

        -  Select communities of 70,000 to 120,000 populations in Zhongshan City as the
           investigators' fields.

        -  Divide them into screening group and control group according to the areas of
           administration

      Participants recruitment

      - Subjects voluntarily attend this screening study

      Informed consent - Informed consent forms will be collected at the recruitment.

      Questionnaires

      - Face-to-face interviews are conducted by well-trained investigators

      Serological tests

        -  Each blood samples will be tested for the surface antigen of the hepatitis B virus
           (HBsAg).

        -  Among those who are positive for HBsAg, further clinical work-ups including
           Alpha-Fetoprotein(AFP) test and ultrasonography for liver exam will be performed and
           high risk group will be selected according to the definition.

        -  HCC diagnosis will be determined according to imaging and/or biopsy result.

        -  The rest of the blood samples will be stored at the biobank of Zhongshan People's
           Hospital.

      Follow up

        -  The cohort will follow up according to the screening protocol. Briefly, Repeated
           check-ups will be performed in 6-months among HBsAg positive group and 3-years among
           HBsAg negative group.

        -  All subjects in the control arm (control communities) will be followed by record linkage
           to Cancer Register and Population Register.
    
  